

Tami Livnat

List of Publications by Citations

Source: <https://exaly.com/author-pdf/3007685/tami-livnat-publications-by-citations.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

156
papers

1,885
citations

23
h-index

38
g-index

187
ext. papers

2,417
ext. citations

4.1
avg, IF

4.8
L-index

#	Paper	IF	Citations
156	Risk factors for recurrent venous thromboembolism in the European collaborative paediatric database on cerebral venous thrombosis: a multicentre cohort study. <i>Lancet Neurology, The</i> , 2007 , 6, 595-603	24.1	153
155	Prevalence, causes, and characterization of factor XI inhibitors in patients with inherited factor XI deficiency. <i>Blood</i> , 2003 , 101, 4783-8	2.2	110
154	Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial. <i>Lancet Haematology, the</i> , 2020 , 7, e18-e27	14.6	74
153	Paediatric cerebral sinus vein thrombosis. A multi-center, case-controlled study. <i>Thrombosis and Haemostasis</i> , 2004 , 92, 713-8	7	67
152	Plasma glutathione peroxidase deficiency and platelet insensitivity to nitric oxide in children with familial stroke. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1999 , 19, 2017-23	9.4	66
151	European evidence-based recommendations for diagnosis and treatment of paediatric antiphospholipid syndrome: the SHARE initiative. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 1637-1641	2.4	59
150	Recombinant activated factor VII and tranexamic acid are haemostatically effective during major surgery in factor XI-deficient patients with inhibitor antibodies. <i>Thrombosis and Haemostasis</i> , 2009 , 102, 487-92	7	56
149	Concomitant infusion of low doses of rFVIIa and FEIBA in haemophilia patients with inhibitors. <i>Haemophilia</i> , 2009 , 15, 904-10	3.3	53
148	Impact of persistent antiphospholipid antibodies on risk of incident symptomatic thromboembolism in children: a systematic review and meta-analysis. <i>Seminars in Thrombosis and Hemostasis</i> , 2011 , 37, 802-9	5.3	44
147	Emicizumab prophylaxis among infants and toddlers with severe hemophilia A and inhibitors-a single-center cohort. <i>Pediatric Blood and Cancer</i> , 2019 , 66, e27886	3	42
146	Long-acting recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in children. Results of a phase 3 trial. <i>Thrombosis and Haemostasis</i> , 2016 , 116, 659-68	7	40
145	Effects of factor VIII inhibitor bypassing activity (FEIBA), recombinant factor VIIa or both on thrombin generation in normal and haemophilia A plasma. <i>Haemophilia</i> , 2008 , 14, 782-6	3.3	37
144	Intracranial haemorrhage in children and adolescents with severe haemophilia A or B - the impact of prophylactic treatment. <i>British Journal of Haematology</i> , 2017 , 179, 298-307	4.5	35
143	Prerequisites for recombinant factor VIIa-induced thrombin generation in plasmas deficient in factors VIII, IX or XI. <i>Journal of Thrombosis and Haemostasis</i> , 2006 , 4, 192-200	15.4	34
142	Emicizumab treatment and monitoring in a paediatric cohort: real-world data. <i>British Journal of Haematology</i> , 2020 , 191, 282-290	4.5	33
141	Timing of inhibitor development in more than 1000 previously untreated patients with severe hemophilia A. <i>Blood</i> , 2019 , 134, 317-320	2.2	32
140	Neonatal IVH--mechanisms and management. <i>Thrombosis Research</i> , 2011 , 127 Suppl 3, S120-2	8.2	31

139	The impact of thrombin generation and rotation thromboelastometry on assessment of severity of factor XI deficiency. <i>Thrombosis Research</i> , 2015 , 136, 465-73	8.2	28
138	Venous thromboembolism in neonates and children. <i>Best Practice and Research in Clinical Haematology</i> , 2012 , 25, 333-44	4.2	28
137	Bodyweight-adjusted rivaroxaban for children with venous thromboembolism (EINSTEIN-Jr): results from three multicentre, single-arm, phase 2 studies. <i>Lancet Haematology</i> , 2019 , 6, e500-e509	14.6	27
136	Developmental hemostasis: A lifespan from neonates and pregnancy to the young and elderly adult in a European white population. <i>Blood Cells, Molecules, and Diseases</i> , 2017 , 67, 2-13	2.1	25
135	Hemostasis and thrombosis in critically ill children. <i>Seminars in Thrombosis and Hemostasis</i> , 2008 , 34, 451-53	5.8	25
134	Inhibitor incidence in an unselected cohort of previously untreated patients with severe haemophilia B: a PedNet study. <i>Haematologica</i> , 2021 , 106, 123-129	6.6	23
133	A highly sensitive thrombin generation assay for assessment of recombinant activated factor VII therapy in haemophilia patients with an inhibitor. <i>Thrombosis and Haemostasis</i> , 2011 , 105, 688-95	7	23
132	Association between hyperflexibility of the thumb and an unexplained bleeding tendency: is it a rule of thumb?. <i>British Journal of Haematology</i> , 1998 , 101, 260-3	4.5	21
131	Thrombophilia does not increase risk for neonatal complications in preterm infants. <i>Thrombosis and Haemostasis</i> , 2003 , 90, 823-8	7	21
130	Rivaroxaban for treatment of pediatric venous thromboembolism. An Einstein-Jr phase 3 dose-exposure-response evaluation. <i>Journal of Thrombosis and Haemostasis</i> , 2020 , 18, 1672-1685	15.4	20
129	Thrombin generation as a predictor of thromboembolic events in multiple myeloma patients. <i>Blood Cells, Molecules, and Diseases</i> , 2017 , 65, 1-7	2.1	19
128	Efficacy of topical aflibercept versus topical bevacizumab for the prevention of corneal neovascularization in a rat model. <i>Experimental Eye Research</i> , 2016 , 146, 224-232	3.7	18
127	Risk factors for symptomatic venous and arterial thromboembolism in newborns, children and adolescents - What did we learn within the last 20years?. <i>Blood Cells, Molecules, and Diseases</i> , 2017 , 67, 18-22	2.1	17
126	Mode of delivery in hemophilia: vaginal delivery and Cesarean section carry similar risks for intracranial hemorrhages and other major bleeds. <i>Haematologica</i> , 2019 , 104, 2100-2106	6.6	17
125	In vitro evaluation of clot quality and stability in a model of severe thrombocytopenia: effect of fibrinogen, factor XIII and thrombin-activatable fibrinolysis inhibitor. <i>Blood Transfusion</i> , 2014 , 12, 78-84	3.6	17
124	Laboratory testing in hemophilia: Impact of factor and non-factor replacement therapy on coagulation assays. <i>Journal of Thrombosis and Haemostasis</i> , 2020 , 18, 1242-1255	15.4	16
123	Combined administration of FVIII and rFVIIa improves haemostasis in haemophilia A patients with high-responding inhibitors--a thrombin generation-guided pilot study. <i>Haemophilia</i> , 2013 , 19, 782-9	3.3	16
122	Impact of high-risk thrombophilia status on recurrence among children with a first non-central-venous-catheter-associated VTE: an observational multicentre cohort study. <i>British Journal of Haematology</i> , 2016 , 175, 133-40	4.5	15

121	Health-related quality of life in paediatric haemophilia B patients treated with rIX-FP. <i>Haemophilia</i> , 2019 , 25, 45-53	3.3	15
120	Insights into neonatal thrombosis. <i>Thrombosis Research</i> , 2019 , 181 Suppl 1, S33-S36	8.2	14
119	Thrombosis in pediatric patients with leukemia. <i>Thrombosis Research</i> , 2018 , 164 Suppl 1, S94-S97	8.2	13
118	Hemostasis in the Very Young. <i>Seminars in Thrombosis and Hemostasis</i> , 2018 , 44, 617-623	5.3	13
117	Bleeding issues in neonates and infants - update 2015. <i>Thrombosis Research</i> , 2015 , 135 Suppl 1, S41-3	8.2	13
116	Desmoplastic infantile ganglioglioma. <i>Acta Oncologica</i> , 1997 , 36, 655-7	3.2	13
115	Fetal and neonatal thrombophilia. <i>Obstetrics and Gynecology Clinics of North America</i> , 2006 , 33, 457-66	3.3	13
114	Bevacizumab clearance through the iridocorneal angle following intravitreal injection in a rat model. <i>Experimental Eye Research</i> , 2016 , 145, 412-416	3.7	13
113	Impact of gender on safety and efficacy of Rivaroxaban in adolescents & young adults with venous thromboembolism. <i>Thrombosis Research</i> , 2016 , 148, 145-151	8.2	13
112	Recurrent stroke: the role of thrombophilia in a large international pediatric stroke population. <i>Haematologica</i> , 2019 , 104, 1676-1681	6.6	12
111	The hemostatic efficacy of chitosan-pads in hemodialysis patients with significant bleeding tendency. <i>Journal of Vascular Access</i> , 2017 , 18, 220-224	1.8	12
110	Inhibitors in Hemophilia: Treatment Challenges and Novel Options. <i>Seminars in Thrombosis and Hemostasis</i> , 2018 , 44, 544-550	5.3	12
109	The Edoxaban Hokusai VTE PEDIATRICS Study: An open-label, multicenter, randomized study of edoxaban for pediatric venous thromboembolic disease. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020 , 4, 886-892	5.1	11
108	Effect of erythropoietin on healing of corneal epithelial defects in rabbits. <i>Ophthalmic Research</i> , 2013 , 50, 129-33	2.9	11
107	VEGF Mediates ApoE4-Induced Neovascularization and Synaptic Pathology in the Choroid and Retina. <i>Current Alzheimer Research</i> , 2015 , 12, 323-34	3	11
106	Emicizumab prophylaxis: Prospective longitudinal real-world follow-up and monitoring. <i>Haemophilia</i> , 2021 , 27, 383-391	3.3	11
105	Intraventricular haemorrhage in preterm infants--can we improve outcome by addressing coagulation?. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2015 , 28 Suppl 1, 2265-7	2	10
104	Thrombophilia testing in children: What and when should be tested?. <i>Thrombosis Research</i> , 2018 , 164, 75-78	8.2	10

103	In vitro characterization of MOD-5014, a novel long-acting carboxy-terminal peptide (CTP)-modified activated FVII. <i>Haemophilia</i> , 2018 , 24, 477-486	3.3	10
102	<i>Helicobacter pylori</i> -associated gastric lymphoma in a girl. <i>Pediatric Hematology and Oncology</i> , 1997 , 14, 177-80	1.7	10
101	High-dose recombinant factor VIIa therapy in hemophilia patients with inhibitors. <i>Seminars in Hematology</i> , 2006 , 43, S108-10	4	10
100	Safety and efficacy of anticoagulant therapy in pediatric catheter-related venous thrombosis (EINSTEIN-Jr CVC-VTE). <i>Blood Advances</i> , 2020 , 4, 4632-4639	7.8	10
99	Assessment of Functional Fibrinolysis in Cord Blood Using Modified Thromboelastography. <i>Pediatric Blood and Cancer</i> , 2016 , 63, 839-43	3	10
98	Emicizumab prophylaxis in haemophilia patients older than 50 years with cardiovascular risk factors: Real-world data. <i>Haemophilia</i> , 2021 , 27, 253-260	3.3	10
97	Impact of high risk thrombophilia status on recurrence among children and adults with VTE: An observational multicenter cohort study. <i>Blood Cells, Molecules, and Diseases</i> , 2016 , 62, 24-31	2.1	9
96	Risk Factors for the Progression from Low to High Titres in 260 Children with Severe Haemophilia A and Newly Developed Inhibitors. <i>Thrombosis and Haemostasis</i> , 2017 , 117, 2274-2282	7	9
95	Recombinant factor VIIa treatment for asymptomatic factor VII deficient patients going through major surgery. <i>Blood Coagulation and Fibrinolysis</i> , 2012 , 23, 379-87	1	9
94	PROTECT VIII Kids: BAY 94-9027 (PEGylated Recombinant Factor VIII) safety and efficacy in previously treated children with severe haemophilia A. <i>Haemophilia</i> , 2020 , 26, e55-e65	3.3	8
93	Rotation thromboelastometry analysis of clot formation and fibrinolysis in severe thrombocytopenia: effect of fibrinogen, activated prothrombin complex concentrate, and thrombin-activatable fibrinolysis inhibitor. <i>International Journal of Laboratory Hematology</i> , 2015 , 37, 521-9	2.5	8
92	Single-dose recombinant activated factor VII therapy in hemophilia patients with inhibitors. <i>Seminars in Hematology</i> , 2008 , 45, S38-41	4	8
91	Low Concentrations of Recombinant Factor VIIa May Improve the Impaired Thrombin Generation of Glanzmann Thrombasthenia Patients. <i>Thrombosis and Haemostasis</i> , 2019 , 119, 117-127	7	8
90	Primary prophylaxis for children with severe congenital factor VII deficiency - Clinical and laboratory assessment. <i>Blood Cells, Molecules, and Diseases</i> , 2017 , 67, 86-90	2.1	7
89	Rare bleeding disorders-old diseases in the era of novel options for therapy. <i>Blood Cells, Molecules, and Diseases</i> , 2017 , 67, 63-68	2.1	7
88	Cerebral and portal vein thrombosis, macrocephaly and atypical absence seizures in Glycosylphosphatidyl inositol deficiency due to a PIGM promoter mutation. <i>Molecular Genetics and Metabolism</i> , 2019 , 128, 151-161	3.7	7
87	Long-Term Safety and Efficacy of Recombinant Coagulation Factor IX Albumin Fusion Protein (rIX-FP) in Previously Treated Pediatric Patients with Hemophilia B: Results from a Phase 3b Extension Study. <i>Thrombosis and Haemostasis</i> , 2020 , 120, 599-606	7	7
86	The effects of the apoE4 genotype on the developing mouse retina. <i>Experimental Eye Research</i> , 2016 , 145, 17-25	3.7	7

85	An extra X does not prevent acquired hemophilia - Pregnancy-associated acquired hemophilia A. <i>Thrombosis Research</i> , 2017 , 151 Suppl 1, S82-S85	8.2	6
84	Quantification of specific T and B cells immunological markers in children with chronic and transient ITP. <i>Pediatric Blood and Cancer</i> , 2017 , 64, e26646	3	6
83	Single Low Dose of rFVIIa Combined with Antifibrinolytic Agent is a Simple and Safe Treatment for Factor XI-Deficient Patients undergoing Surgery. <i>Thrombosis and Haemostasis</i> , 2019 , 119, 1927-1932	7	6
82	Comparison of Subconjunctival Aflibercept and Betamethasone for the Treatment of Formed Corneal Neovascularization in a Rabbit Model. <i>Ophthalmic Research</i> , 2019 , 62, 116-122	2.9	6
81	Thrombin generation in plasma of patients with haemophilia A and B with inhibitors: Effects of bypassing agents and antithrombin reduction. <i>Blood Cells, Molecules, and Diseases</i> , 2020 , 82, 102416	2.1	6
80	Long-term safety and efficacy of N8-GP in previously treated pediatric patients with hemophilia A: Final results from pathfinder5. <i>Journal of Thrombosis and Haemostasis</i> , 2020 , 18 Suppl 1, 15-25	15.4	6
79	Effect of Histone Deacetylase Inhibitor, Butyroyloxymethyl-Diethyl Phosphate (AN-7), on Corneal Neovascularization in a Mouse Model. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2017 , 33, 480-486	2.6	5
78	High adherence to prophylaxis regimens in haemophilia B patients receiving rIX-FP: Evidence from clinical trials and real-world practice. <i>Haemophilia</i> , 2020 , 26, 637-642	3.3	5
77	Thromboelastography as a Surrogate Marker of Perisurgical Hemostasis in Gaucher Disease. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2016 , 22, 693-7	3.3	5
76	Correlation between Interleukin-6 and Thrombin-Antithrombin III Complex Levels in Retinal Diseases. <i>Current Eye Research</i> , 2017 , 42, 1269-1272	2.9	5
75	Combination of hemostatic therapies for treatment of patients with hemophilia A and inhibitors. <i>Blood Cells, Molecules, and Diseases</i> , 2017 , 66, 1-5	2.1	5
74	Inflammation, angiogenesis and coagulation interplay in a variety of retinal diseases. <i>Acta Ophthalmologica</i> , 2019 , 98, e559	3.7	5
73	The Histone Deacetylase Inhibitor AN7, Attenuates Choroidal Neovascularization in a Mouse Model. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	4
72	Mobile Laser Indirect Ophthalmoscope: For the Induction of Choroidal Neovascularization in a Mouse Model. <i>Current Eye Research</i> , 2017 , 42, 1545-1551	2.9	4
71	Changes in Retinal Function and Cellular Remodeling Following Experimental Retinal Detachment in a Rabbit Model. <i>Journal of Ophthalmology</i> , 2017 , 2017, 4046597	2	4
70	Bleeding issues in neonates, infants and young children. <i>Thrombosis Research</i> , 2009 , 123 Suppl 2, S35-7	8.2	4
69	Transcleral approach for closing retinal tears using DuraSeal hydrogel sealant. <i>Indian Journal of Ophthalmology</i> , 2018 , 66, 238-243	1.6	4
68	Prophylaxis in children with haemophilia in an evolving treatment landscape. <i>Haemophilia</i> , 2021 , 27, 889-896	3.9	4

67	The Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Patients Hospitalized with Acute Pulmonary Embolism. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	4
66	Quantitation of bleeding symptoms in a national registry of patients with inherited platelet disorders. <i>Blood Cells, Molecules, and Diseases</i> , 2017 , 67, 59-62	2.1	3
65	Influence of factor 5 rs6025 and factor 2 rs1799963 mutation on inhibitor development in patients with hemophilia A--an Israeli-German multicenter database study. <i>Thrombosis Research</i> , 2014 , 133, 544-9	8.2	3
64	Severe factor X deficiency in three unrelated Palestinian patients is caused by homozygosity for the mutation c302delG--correlation with thrombin generation and thromboelastometry. <i>Blood Coagulation and Fibrinolysis</i> , 2011 , 22, 673-9	1	3
63	Hemostasis and thrombosis in pediatric patients: special issues and unique concerns. <i>Seminars in Thrombosis and Hemostasis</i> , 2011 , 37, 721-2	5.3	3
62	Thrombin Generation Test Can Predict Bleeding Tendency In Patients With Severe Factor XI Deficiency. <i>Blood</i> , 2013 , 122, 3600-3600	2.2	3
61	Fitusiran, an Investigational siRNA Therapeutic Targeting Antithrombin for the Treatment of Hemophilia: First Results from a Phase 3 Study to Evaluate Efficacy and Safety in People with Hemophilia a or B without Inhibitors (ATLAS-A/B). <i>Blood</i> , 2021 , 138, LBA-3-LBA-3	2.2	3
60	Cancer-associated thrombosis in pediatric patients. <i>Thrombosis Research</i> , 2020 , 191 Suppl 1, S22-S25	8.2	3
59	The potential role of emicizumab prophylaxis in severe von Willebrand disease. <i>Blood Cells, Molecules, and Diseases</i> , 2021 , 87, 102530	2.1	3
58	Heparin-induced thrombocytopenia complicating children after the Fontan procedure: Single-center experience and review of the literature. <i>Congenital Heart Disease</i> , 2018 , 13, 16-25	3.1	3
57	Heart Rate and Mortality in Patients With Acute Symptomatic Pulmonary Embolism. <i>Chest</i> , 2021 ,	5.3	3
56	Real-World Data on Bleeding Patterns of Hemophilia A Patients Treated with Emicizumab. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	3
55	Activated protein C induces suppression and regression of choroidal neovascularization- A murine model. <i>Experimental Eye Research</i> , 2019 , 186, 107695	3.7	2
54	Skin Necrosis and Purpura Fulminans in Children With and Without Thrombophilia--A Tertiary Center's Experience. <i>Pediatric Hematology and Oncology</i> , 2015 , 32, 505-10	1.7	2
53	Treatment tailoring for factor V deficient patients and perioperative management using global hemostatic coagulation assays. <i>Blood Cells, Molecules, and Diseases</i> , 2018 , 71, 5-10	2.1	2
52	A novel approach using ancillary tests to guide treatment of Glanzmann thrombasthenia patients undergoing surgical procedures. <i>Blood Cells, Molecules, and Diseases</i> , 2018 , 72, 44-48	2.1	2
51	Allergy and inhibitors in hemophilia - a rare complication with potential novel solutions. <i>Blood Cells, Molecules, and Diseases</i> , 2020 , 80, 102370	2.1	2
50	Women with Hemophilia: Case Series of Reproductive Choices and Review of Literature. <i>TH Open</i> , 2021 , 5, e183-e187	2.7	2

49	Mutations in RASGRP2 gene identified in patients misdiagnosed as Glanzmann thrombasthenia patients. <i>Blood Cells, Molecules, and Diseases</i> , 2021 , 89, 102560	2.1	2
48	Population pharmacokinetic (PopPK) modelling indicates that patients switching to BAY 81-8973 from rFVIII-FS can continue their dosing schedule with improved protection. <i>Haemophilia</i> , 2020 , 26, e145 ^{3,3} e147 ²		
47	Role of prothrombin 19911 A>G polymorphism, blood group and male gender in patients with venous thromboembolism: Results of a German cohort study. <i>Journal of Thrombosis and Thrombolysis</i> , 2021 , 51, 494-501	5.1	2
46	Catheter-directed thrombolysis for in situ pulmonary artery thrombosis in children. <i>Annals of Pediatric Cardiology</i> , 2021 , 14, 211-214	0.8	2
45	A man-made disease: Fetal neonatal alloimmune thrombocytopenia due to incompatibility between oocyte donor and gestational mother. <i>Pediatric Blood and Cancer</i> , 2017 , 64, e26447	3	1
44	Longitudinal Assessment of Thrombin Generation in Patients with Hemophilia Receiving Fitusiran Prophylaxis: Phase II Study Results. <i>Blood</i> , 2020 , 136, 36-37	2.2	1
43	Validation of a predictive model for identifying an increased risk for recurrence in adolescents and young adults with a first provoked thromboembolism.. <i>Blood Cells, Molecules, and Diseases</i> , 2022 , 94, 102651	2.1	1
42	BAY 94-9027 Provides Safe and Effective Long-Term Prophylaxis in Pediatric Patients: Results from the PROTECT VIII Kids Extension Study. <i>Blood</i> , 2020 , 136, 40-41	2.2	1
41	European Collaborative Paediatric Database on Cerebral Sinus Venous Thrombosis (CVT): Risk of Recurrent Venous Thrombosis (Update 2005).. <i>Blood</i> , 2005 , 106, 1629-1629	2.2	1
40	Post-Thrombotic Syndrome (PTS) in Children: A Systematic Review of Prevalence, Validity of Outcome Measures, and Prognostic Factors.. <i>Blood</i> , 2009 , 114, 2978-2978	2.2	1
39	PROTECT VIII kids extension study: Long-term safety and efficacy of BAY 94-9027 (damoctocog alfa pegol) in children with severe haemophilia A. <i>Haemophilia</i> , 2021 , 27, 434-444	3.3	1
38	Spinal Epidural Hematoma Following Cupping Glass Treatment in an Infant With Hemophilia A. <i>Pediatric Blood and Cancer</i> , 2016 , 63, 1120-2	3	1
37	Dabigatran etexilate and treatment of acute venous thromboembolism in children. <i>Lancet Haematology,the</i> , 2021 , 8, e2-e3	14.6	1
36	Pediatric immune thrombocytopenia: apoptotic markers may help in predicting the disease course. <i>Pediatric Research</i> , 2021 , 90, 93-98	3.2	1
35	Alternative treatment options for pediatric hemophilia B patients with high-responding inhibitors: A thrombin generation-guided study. <i>Pediatric Blood and Cancer</i> , 2018 , 65, e27381	3	1
34	From thrombasthenia to next generation thrombocytopenia: Neonatal alloimmune thrombocytopenia induced by maternal Glanzmann thrombasthenia. <i>Pediatric Blood and Cancer</i> , 2018 , 65, e27376	3	1
33	Dehydration as a Rare Cause of Pulmonary Artery Thrombosis in a 2-Week-Old Term Neonate. <i>Journal of Pediatric Intensive Care</i> , 2018 , 7, 102-105	1	1
32	Molecular Mechanisms of Skewed X-Chromosome Inactivation in Female Hemophilia Patients-Lessons From Wide Genome Analyses. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	1

31	Real-World Rates of Bleeding, Factor VIII Use, and Quality of Life in Individuals with Severe Haemophilia A Receiving Prophylaxis in a Prospective, Noninterventional Study.. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	1
30	Continued benefit demonstrated with BAY 81-8973 prophylaxis in previously treated children with severe haemophilia A: Interim analysis from the LEOPOLD Kids extension study. <i>Thrombosis Research</i> , 2020 , 189, 96-101	8.2	0
29	Essential thrombocythemia A retrospective case series. <i>Pediatric Blood and Cancer</i> , 2020 , 67, e28183	3	0
28	Severe Protein C Deficiency due to Novel Biallelic Variants in PROC and Their Phenotype Correlation. <i>Acta Haematologica</i> , 2021 , 144, 327-331	2.7	0
27	Novel mutation in coagulation factor VII (Carmel mutation): Identification and characterization. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021 , 5, e12407	5.1	0
26	A Proposed Role of Surfactant in Platelet Function and Treatment of Pulmonary Hemorrhage in Preterm and Term Infants. <i>Acta Haematologica</i> , 2018 , 140, 215-220	2.7	0
25	Pediatric severe factor XI deficiency: A multicenter study.. <i>Pediatric Blood and Cancer</i> , 2021 , e29545	3	0
24	Anti-TFPI for hemostasis induction in patients with rare bleeding disorders, an ex vivo thrombin generation (TG) guided pilot study.. <i>Blood Cells, Molecules, and Diseases</i> , 2022 , 95, 102663	2.1	0
23	Emicizumab state-of-the-art update.. <i>Haemophilia</i> , 2022 , 28 Suppl 4, 103-110	3.3	0
22	Cerebral sinovenous thrombosis in children and neonates33-46		
21	Pediatric thrombophilia evaluation: Considerations for primary and secondary venous thromboembolism prevention133-141		
20	Author@ reply to: Al-Abdi SY. Virus-inactivated plasma and intraventricular hemorrhage in preterm neonates. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2014 , 27, 1289	2	
19	Improvement of Efficacy Outcomes in Patients Who Switched from Sucrose-Formulated rFVIII to BAY 81-8973 Prophylaxis in the LEOPOLD Clinical Trials. <i>Blood</i> , 2020 , 136, 20-21	2.2	
18	Relationship between Endogenous, Transgene FVIII Expression and Bleeding Events Following Valoctocogene Roxaparvovec Gene Transfer for Severe Hemophilia A: A Post-Hoc Analysis of the GENER8-1 Phase 3 Trial. <i>Blood</i> , 2021 , 138, 3972-3972	2.2	
17	Genotype-Phenotype Relationship Among 1200 Unrelated White Patients with Inherited FVII Deficiency: A Three-Center Database Study. <i>Blood</i> , 2021 , 138, 589-589	2.2	
16	Platelet Adrenergic Receptor Dysfunction Is Associated with Both Aggregation and Adhesion Defects: Application of the Cone and Plate(let) Analyzer for Diagnosis and Monitoring of the Response to DDAVP Therapy.. <i>Blood</i> , 2004 , 104, 3039-3039	2.2	
15	European Collaborative Paediatric Database on Cerebral Venous Thrombosis: Risk Factors for Recurrent Venous Thromboembolism.. <i>Blood</i> , 2006 , 108, 276-276	2.2	
14	99.3% of Inhibitors in Severe Hemophilia a Develop before Exposure Day 75. Time to Change Definition of Previously Treated Patients; Data from 1038 Patients with Severe Hemophilia a of the Pednet Registry. <i>Blood</i> , 2018 , 132, 2472-2472	2.2	

- 13 Recurrent Stroke: The Role of Thrombophilia in a Large International Pediatric Stroke Population. *Blood*, **2018**, 132, 3808-3808 2.2
- 12 A Single Low-Dose of Methylphenidate Improves Abnormal Visual Field Testing. *Current Eye Research*, **2021**, 46, 1232-1239 2.9
- 11 Impact of SERPINC1, PROC and PROS1 Mutations on the Thrombotic Phenotype in Children with Venous Thromboembolism: An Observational Multicenter Cohort Study. *Blood*, **2014**, 124, 583-583 2.2
- 10 Efficacy and Safety of Rivaroxaban: An Observational multicenter Cohort Study Reporting the Routine Use in Adolescents & Adults with DVT. *Blood*, **2014**, 124, 5083-5083 2.2
- 9 Influence of Gender and Coagulation Factors on Efficacy and Safety of Rivaroxaban in Adolescents & Young Adults with Venous Thromboembolism. *Blood*, **2015**, 126, 4729-4729 2.2
- 8 Neonatal circumcision in patients with haemophilia is safe in a single centre experience. *The Journal of Haemophilia Practice*, **2017**, 4, 32-34 0.2
- 7 Validation of a Predictive Model for Identifying An Increased Risk for Thromboembolism in Children with Acute Lymphoblastic Leukemia: Results of a Multicenter Cohort Study. *Blood*, **2008**, 112, 524-524 2.2
- 6 Risk Factors for Central Venous Line-Related Deep Vein Thrombosis and Occlusions in the Israeli Pediatric Oncology Registry.. *Blood*, **2008**, 112, 1814-1814 2.2
- 5 Impact of Thrombophilia On Arterial Ischemic Stroke or Cerebral Venous Sinus Thromboses in Children: A Systematic Review & Meta-Analysis of Observational Studies.. *Blood*, **2009**, 114, 3993-3993 2.2
- 4 Rate of Inhibitor Development in Hemophilia A Patients Treated with Plasma Derived or Recombinant Factor VIII Concentrates. A Systematic Review of the Literature.. *Blood*, **2009**, 114, 3154-3154 2.2
- 3 Strategies for Securing and Maintaining Predictable Efficacy with Recombinant Activated Factor VII in On-Demand Treatment of Haemophilia Patients with Inhibitors.. *Blood*, **2009**, 114, 4443-4443 2.2
- 2 A Genetic Origin? Purpura Fulminans. *American Journal of Medicine*, **2019**, 132, 327-328 2.4
- 1 Evaluation of pro-angiogenic and pro-coagulant activity of irradiated and non irradiated stored blood used in transfusion practice. *Journal of Clinical Oncology*, **2004**, 22, 9710-9710 2.2